Metallic radionuclide-labeled tetrameric 2,6-diisopropylphenyl azides for cancer treatment.

This study proposes a new method for radionuclide therapy that involves the use of oligomeric 2,6-diisopropylphenyl azides and a chelator to form stable complexes with metallic radionuclides. The technique works by taking advantage of the endogenous acrolein produced by cancer cells. The azides react with the acrolein to give a diazo derivative that immediately attaches to the nearest organelle, effectively anchoring the radionuclide within the tumor. Preliminary in vivo experiments were conducted on a human lung carcinoma xenograft model, demonstrating the feasibility of this approach for cancer treatment.

Citation

Yudai Ode, Ambara R Pradipta, Akihiro Ishiwata, Akihiro Nambu, Kazunobu Ohnuki, Hiroshi Mizuma, Hiromitsu Haba, Katsunori Tanaka. Metallic radionuclide-labeled tetrameric 2,6-diisopropylphenyl azides for cancer treatment. Chemical communications (Cambridge, England). 2024 Mar 19;60(24):3291-3294

Mesh Tags

Substances

PMID: 38421438

search → result